ES2578729T3 - Agente terapéutico para enfermedades relacionadas con el hígado - Google Patents

Agente terapéutico para enfermedades relacionadas con el hígado Download PDF

Info

Publication number
ES2578729T3
ES2578729T3 ES10812011.4T ES10812011T ES2578729T3 ES 2578729 T3 ES2578729 T3 ES 2578729T3 ES 10812011 T ES10812011 T ES 10812011T ES 2578729 T3 ES2578729 T3 ES 2578729T3
Authority
ES
Spain
Prior art keywords
therapeutic agent
related diseases
liver related
liver
vein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10812011.4T
Other languages
English (en)
Inventor
Akifumi Matsuyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Air Machine Service Ltd
Original Assignee
Osaka Air Machine Service Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Air Machine Service Ltd filed Critical Osaka Air Machine Service Ltd
Application granted granted Critical
Publication of ES2578729T3 publication Critical patent/ES2578729T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0667Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un agente terapéutico que comprende células progenitoras multilinaje derivadas de tejido adiposo para su uso en el tratamiento de una enfermedad relacionada con el hígado, donde el agente es para administrar a través de la vena porta, a través de una vena, a través de una arteria, o a través de un conducto biliar.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10812011.4T 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado Active ES2578729T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009198166 2009-08-28
JP2009198166 2009-08-28
PCT/JP2010/064623 WO2011024962A1 (ja) 2009-08-28 2010-08-27 肝臓関連疾患治療薬

Publications (1)

Publication Number Publication Date
ES2578729T3 true ES2578729T3 (es) 2016-07-29

Family

ID=43628060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10812011.4T Active ES2578729T3 (es) 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado

Country Status (5)

Country Link
US (1) US8784803B2 (es)
EP (1) EP2471542B1 (es)
JP (1) JP4965000B2 (es)
ES (1) ES2578729T3 (es)
WO (1) WO2011024962A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554176B1 (en) * 2011-08-04 2016-07-27 ETHIANUM Betriebsgesellschaft mbH & Co. KG Means for liver regeneration
US9533013B2 (en) * 2013-03-13 2017-01-03 University Of North Carolina At Chapel Hill Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
US10537525B2 (en) 2015-04-14 2020-01-21 Mayo Foundation For Medical Education And Research Methods and materials for delivering agents to liver tissue
JP6923137B2 (ja) * 2018-06-15 2021-08-18 有限会社大阪空気機械サービス 組織治癒剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286118T1 (de) * 1998-03-13 2005-01-15 Osiris Therapeutics Inc Anwendungen für humane nicht autologe, mesenchymale stammzellen
US20030082152A1 (en) * 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
US20030161816A1 (en) * 2001-12-07 2003-08-28 Fraser John K. Systems and methods for treating patients with processed lipoaspirate cells
ES2257225B1 (es) * 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
JP2009535035A (ja) 2006-04-25 2009-10-01 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 肝臓再生における脂肪細胞由来成体幹細胞
PL2047414T3 (pl) 2006-08-03 2014-03-31 Smart Packaging Solutions Sps Zabezpieczony dokument, zwłaszcza paszport elektroniczny ze wzmocnionym zabezpieczeniem
EP2166084A4 (en) * 2007-06-14 2010-06-23 Found Biomedical Res & Innov MULTIPOTENTE PRECURSOR CELLS FROM FAT
JP5338322B2 (ja) 2008-01-11 2013-11-13 ダイキン工業株式会社 空気調和装置の室内ユニット

Also Published As

Publication number Publication date
US8784803B2 (en) 2014-07-22
JPWO2011024962A1 (ja) 2013-01-31
EP2471542A1 (en) 2012-07-04
US20120156181A1 (en) 2012-06-21
WO2011024962A1 (ja) 2011-03-03
EP2471542B1 (en) 2016-04-27
EP2471542A4 (en) 2013-11-20
JP4965000B2 (ja) 2012-07-04

Similar Documents

Publication Publication Date Title
TN2021000028A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
UA99152C2 (ru) Восстановление и регенерация почечной ткани с использованием клеток, полученных с человеческой ткани пупочного канатика
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
RU2012131164A (ru) (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
SG10201804772UA (en) Method of imaging living tissue